Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Videos|April 27, 2022

BioTissue continues the rollout of its corporate rebranding

Author(s)Kassi Filkins

Earlier this year, BioTissue announced the corporate rebrand of its new customer facing entity, including carrying the name over to its surgical business formally known as Amniox Medical. Randy Mansfield, VP of marketing for BioTissue, shares an update at ASCRS 2022.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

ByLucia Gambuzza

July 30th 2026

QandA with Ping Moore, OD

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

ByYun Ping Moore, OD,Lucia Gambuzza

Published: July 23rd 2026 | Updated: July 23rd 2026

(Image courtesy of Peter J. McDonnell, MD) Why aren’t there enough ophthalmologists?

Why aren’t there enough ophthalmologists?

ByPeter J. McDonnell, MD

July 20th 2026

Personalizing dry eye treatment by addressing disease at its source

ByMarjan Farid, MD

July 17th 2026

Q&A with Esen Akpek, MD | Ophthalmology Times

Root cause–based dry eye classification and the shift toward precision medicine

ByLucia Gambuzza,Esen K. Akpek, MD

July 15th 2026

Latest CME

Join Us at The Ophthalmology Meeting This October in New Orleans

In-Person + Virtual Event

Join Us at The Ophthalmology Meeting This October in New Orleans

October 9-11, 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Eye Care Network - Ophthalmology Times

Retina Society 2026: Non-invasive electrical stimulation therapy for intermediate dry AMD: improved retinal health and visual acuity

Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP

Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial

Beyond the phenotype: Aqueous humor sampling moves retinoblastoma toward personalized therapy

Retina Society 2026: LUGANO secondary data show reduced treatment burden with vorolanib insert despite missed primary end point